CASP3 and epilepsy: Co-administration of chondroitin sulfate (100 & 200 mg/kg; p.o.)significantly (p < 0.05 each) and dose-dependently, along with the reference drug valproate (110 mg kg−1; (i.p.)), attenuated the levels of caspase-3 when compared with the PTZ control group, representing the neuroprotective effect of chondroitin sulfate in epilepsy (Table 3).